<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/rss20.xsl" media="screen"?>
<rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <atom:link href="http://xagenafarmacia.myblog.it/index.rss" rel="self" type="application/rss+xml" />
        <title>Xagena Farmacia</title>
        <description>Corretto impiego dei farmaci</description>
        <link>http://xagenafarmacia.myblog.it/</link>
        <lastBuildDate>Sun, 20 May 2012 22:24:45 +0200</lastBuildDate>
        <generator>myblog.it</generator>
        <copyright>All Rights Reserved</copyright>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/05/20/malattie-reumatiche-notizie.html</guid>
                <title>Malattie reumatiche Notizie</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/05/20/malattie-reumatiche-notizie.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sun, 20 May 2012 02:09:00 +0200</pubDate>
                <description>
                    &lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.reumatologia.net/index.php?view=18265&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Spondilite anchilosante in terapia con Adalimumab: nefrite interstiziale granulomatosa indotta da farmaci&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Gli inibitori del TNF-alfa ( fattore di necrosi tumorale ) sono impiegati nel trattamento dell’artrite reumatoide, psoriasi, artrite psoriasica, malattia di Crohn, spondilite anchilosante e artrite giovanile idiopatica.L'uso di inibitori del TNF è associato all'induzione di autoimmunità ( lupus eritematoso sistemico, vasculiti, psoriasi e sarcoidosi / granulomi sarcoido-simil [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.reumatologia.net/?view=18265&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.reumatologia.net/index.php?view=17737&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Vioxx può causare eventi avversi cardiovascolari anche dopo la sospensione &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;L'antinfiammatorio Vioxx ( Rofecoxib ) potrebbe essere causa di trombosi, e forse responsabile di esiti fatali, anche nei pazienti che hanno dismesso il farmaco.Queste le conclusioni ottenute analizzando i dati messi a disposizione dalla società produttrice del farmaco, Merck &amp;amp; Co, nel contenzioso con migliaia di pazienti che si sono ritenuti danneggiati dal Vioxx.Nel [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.reumatologia.net/?view=17737&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.reumatologia.net/index.php?cat=farmaci&amp;amp;view=19038&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Tanezumab per il trattamento del dolore da osteoartrosi del ginocchio&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;L'aumento dell'espressione del fattore di crescita nervoso ( NGF ) nel tessuto danneggiato o infiammato è associato a un aumento del dolore.Uno studio proof-of-concept ha valutato la sicurezza e l’efficacia analgesica di Tanezumab, un anticorpo monoclonale umanizzato che lega ed inibisce il fattore di crescita nervoso.In totale, 450 pazienti con osteoa [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.reumatologia.net/?view=19038&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/04/29/farmacia-notizie-parte-2.html</guid>
                <title>Farmacia Notizie - Parte 2</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/04/29/farmacia-notizie-parte-2.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sun, 29 Apr 2012 01:34:00 +0200</pubDate>
                <description>
                    &lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=29&amp;amp;view=15696&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Interazioni farmacologiche: evitare l’uso concomitante di Omeprazolo e di Clopidogrel&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Secondo l’FDA ( Food and Drug Administration ) i pazienti dovrebbero evitare di impiegare il riduttore dell’acidità di stomaco Omeprazolo ( Prilosec; in Italia: Antra, Losec ) con l’antiaggregante piastrinico Clopidogrel ( Plavix ).Nuovi dati suggeriscono che quando i pazienti prendono sia Omeprazolo che Clopidogrel, l’attività antiaggregante del Clopidogrel può ridurs [...] &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15696&amp;amp;page=29&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=29&amp;amp;view=15737&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Depressione: in alcuni pazienti in trattamento con Desipramina le crisi convulsive precedono le disritmia cardiaca e la morte&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Sanofi-Aventis ha informato i medici riguardo a Desipramina ( Norpramin; in Italia: Nortimil ), un farmaco che trova indicazione nella depressione.Estrema cautela dovrebbe essere impiegata quando la Desipramina è impiegata in pazienti che hanno una storia familiare di morte improvvisa, disritmie cardiache, e disturbi di conduzione cardiaca.Inoltre, in alcuni pazienti [...] &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15737&amp;amp;page=29&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=28&amp;amp;view=15740&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Rischio di difetti del tubo neurale dopo esposizione prenatale al Valproato&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;I bambini esposti ai prodotti correlati a Valproato ( Acido Valproico, Divalproex ) nel corso della gravidanza sono ad aumentato rischio di difetti del tubo neurale e di altri importanti difetti di nascita, come difetti craniofacciali e malformazioni cardiovascolari.Il Valproato di sodio è commercializzato come Depacon; Divalproex come Depakote, mentre l’Acido Valproico come D [...] &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15740&amp;amp;page=28&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/04/29/farmacia-notizie-parte-1.html</guid>
                <title>Farmacia Notizie - Parte 1</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/04/29/farmacia-notizie-parte-1.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sun, 29 Apr 2012 01:23:00 +0200</pubDate>
                <description>
                    &lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=28&amp;amp;view=15760&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Rischio epatotossicità con Voltaren gel&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: small;&quot;&gt;Novartis ha informato riguardo a gravi reazioni epatiche dopo applicazione del farmaco Voltaren gel.Voltaren gel è un preparato ad azione antinfiammatoria, che trova indicazione nel sollievo del dolore da osteoartrosi a livello delle ginocchia e delle mani, mediante un trattamento topico.Voltaren non è stato valutato per l’impiego delle articolazioni a livello della col [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15760&amp;amp;page=28&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=27&amp;amp;view=15777&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Potenziale rischio di meningioma con l’uso di Ciproterone ad alto dosaggio&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: small;&quot;&gt;Il Ciproterone acetato è un derivato del progesterone, e possiede effetti progestagenici, antiandrogenici, e antigonadotropici.In Gran Bretagna sono disponibili preparazioni ad alto dosaggio ( Cyprostat-50 e Cyprostat-100 ), che sono indicate nel trattamento del tumore della prostata ( dosaggio: 50-300 mg/die ).Ciproterone acetato è anche disponibile come Andrecur-50, che [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15777&amp;amp;page=27&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=28&amp;amp;view=15772&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Antibiotici: gravi reazioni avverse con Levofloxacina&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: small;&quot;&gt;La Levofloxacina ( Levaquin, Tavanic ) è un antibatterico appartenente alla classe dei fluorochinolonici ed è l’enantiomero levogiro del racemo di Ofloxacina.La Levofloxacina esplica la sua potente attività antibatterica mediante l’inattivazione selettiva della DNA-girasi batterica e della topoisomerasi IV.I più gravi effetti indesiderati associati alla Levofloxacin [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15772&amp;amp;page=28&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/04/19/farmacia-news-medicina-donna.html</guid>
                <title>Farmacia News: medicina donna</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/04/19/farmacia-news-medicina-donna.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Thu, 19 Apr 2012 01:00:42 +0200</pubDate>
                <description>
                    &lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?view=18400&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Emicrania e rischio di ictus emorragico nelle donne&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Uno studio prospettico di coorte ha esaminato l’associazione tra rischio di ictus emorragico e l’emicrania o l’emicrania con aura.Sono state arruolate 27.860 donne di età maggiore o uguale a 45 anni senza ictus o altre malattie maggiori, al basale, e che avevano fornito informazioni su emicrania, status di aura e valori lipidici.Le principali misure di esito er [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/?view=18400&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologiaonline.net/index.php?view=18411&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Gestione dei disordini ipertensivi in gravidanza: sintesi delle linee guida NICE&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;I disturbi ipertensivi della gravidanza coprono uno spettro di condizioni, tra cui ipertensione cronica ( preesistente ), preeclampsia, ipertensione gestazionale.Queste condizioni sono associate a un aumento della mortalità e morbilità perinatale.I disturbi ipertensivi causano un bambino nato morto su 50 bambini normali e il 10% di tutte le nascite pretermine. Inoltre, co [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologiaonline.net/?view=18411&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medicinadonna.it/index.php?page=17&amp;amp;view=52&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Diabete e gravidanza&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Il diabete gestazionale è un’alterata tolleranza glucidica diagnosticata in gravidanza, comprendente sia patologie realmente insorte in gravidanza, sia forme di diabete di tipo 1, 2 o IGT ( ridotta tolleranza glicemica ) precedenti la gestazione ma non diagnosticate. Di solito il diabete viene diagnosticato all’inizio del terzo trimestre, ma esistono casi di esordio p [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medicinadonna.it/index.php?view=52&amp;amp;page=17&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/04/16/farmacia-news.html</guid>
                <title>Farmacia News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/04/16/farmacia-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Mon, 16 Apr 2012 01:18:00 +0200</pubDate>
                <description>
                    &lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=31&amp;amp;view=15468&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Casi di pancreatite acuta in pazienti trattati con Januvia e Janumet&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;L’FDA ( Food and Drug Administration ) sta compiendo una revisione della scheda tecnica di Januvia ( Sitagliptin ) e Janumet ( Sitagliptin e Metformina ) per includere l’informazione su possibile sviluppo di pancreatite acuta nei pazienti che fanno uso di questi farmaci.Sitagliptin, il capostipite di una nuova classe di farmaci denominata inibitori della dipeptidil-peptidasi [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15468&amp;amp;page=31&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt; &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=32&amp;amp;view=15424&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;L’antibiotico Cefaclor associato a reazioni tipo malattia da siero nei bambini&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;L’associazione tra Cefaclor ( Panacef ) e le reazioni simili a malattia da siero, soprattutto nei bambini, è da lungo tempo nota.Queste reazioni sono caratterizzate da rash, che comprendono l’orticaria o l’eritema multiforme, con o senza angioedema, accompagnate da artrite / artralgia, con o senza febbre.Le reazioni sono rare ma si presentano più spesso dopo un seco [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15424&amp;amp;page=32&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=32&amp;amp;view=15426&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Latanoprost e Rosiglitazone sono associati a edema maculare&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;L’edema maculare causa visione offuscata o distorta come conseguenza del rigonfiamento doloroso della macula. La condizione è relativamente comune ed è frequentemente associata a varie condizioni oculari, tra cui la chirurgia della cataratta e la degenerazione maculare associata all’età, e raramente alla tossicità farmacologica.L’edema maculare cronico o le recidive [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15426&amp;amp;page=32&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/04/09/farmaci-news.html</guid>
                <title>Farmaci News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/04/09/farmaci-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Mon, 09 Apr 2012 22:34:44 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/775a46e8c6d09ce5548db66cc249435c.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Aripiprazolo associato a sindrome neurolettica maligna&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/65ddc1f88e46d28edac152bdb47193e0.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;La costipazione indotta dalla Clozapina può essere fatale&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/b803f0a4e6b8514f2dab43eaca581b05.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Più alta incidenza di disfunzione sessuale dopo Escitalopram, rispetto alla Duloxetina, nei pazienti con disturbo depressivo maggiore&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/efee1278c6172f7361d1900617faede2.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Gli antidepressivi SSRI non sembrano associati ad un maggior rischio di suicidio nei pazienti adulti&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/d7ce5233d2702b91fbbe0cf16b19f573.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Antinfiammatori: Tora-Dol e Lixidol associati a gravi reazioni avverse, anche ad esito fatale&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/04/05/diabete-mellito-news.html</guid>
                <title>Diabete mellito News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/04/05/diabete-mellito-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Thu, 05 Apr 2012 01:43:09 +0200</pubDate>
                <description>
                    &lt;div class=&quot;ecxpost&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: xx-large/41px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 57px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 52px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 68px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.diabetologia.net/index.php?view=17579&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Statine e rischio di diabete incidente&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 57px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 52px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Studi clinici sulla terapia a base di statine hanno mostrato risultati contrastanti per quanto riguarda il rischio di sviluppo di diabete mellito in pazienti in trattamento con statine.Uno studio ha valutato mediante una meta-analisi dei dati pubblicati o non-pubblicati se esiste qualche relazione tra uso di statine e sviluppo di diabete.Sono stati identificati 13 stu [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 41px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.diabetologia.net/?view=17579&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: xx-large/41px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 57px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 52px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 68px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.diabetologia.net/index.php?view=17265&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Efficacia della terapia con pompa insulinica con sensore nel diabete mellito di tipo 1&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Le tecnologie sviluppate per il trattamento del diabete mellito di tipo 1 comprendono diverse pompe e pompe con sensori di glucosio.Uno studio, multicentrico, randomizzato e controllato, della durata di 1 anno ha confrontato l’efficacia della terapia basata sull’uso di una pompa con sensore ( terapia con pompa ) con quella di un regime basato su iniezioni multiple di Insulina [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 41px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.diabetologia.net/?view=17265&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: xx-large/41px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 57px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 52px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 68px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.diabetologia.net/index.php?view=17061&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Sviluppo di carcinoma della vescica dopo 2 anni di assunzione dell’antidiabetico Actos&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Actos è stato approvato nel 1999 come terapia aggiuntiva alla dieta e all’esercizio fisico per migliorare il controllo glicemico negli adulti con diabete mellito di tipo 2.Actos, ai dosaggi approvati, riduce l’emoglobina glicosilata ( HbA1c ), rispetto al placebo, in media dell’1.5%.Negli studi preclinici di carcinogenicità riguardanti il Pioglitazone, è stato osse [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 41px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.diabetologia.net/?view=17061&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/04/04/focus-on-medicina.html</guid>
                <title>Focus On: Medicina</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/04/04/focus-on-medicina.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Wed, 04 Apr 2012 01:18:00 +0200</pubDate>
                <description>
                    &lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/41&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; color: #ff0000;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;Priligy nel trattamento dell'eiaculazione precoce: non vale il rischio&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/40&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; color: #ff0000;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;Bypass coronarico: aumento di mortalità con gli Ace inibitori&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;div style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/39&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; color: #ff0000;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;BPCO: il Panel dell'FDA ha votato contro l'approvazione di Roflumilast&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p style=&quot;line-height: 17px; margin: 0px 0px 1.35em;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/38&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; color: #ff0000;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;FDA: dubbi sulla sicurezza degli agonisti GNRH&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p style=&quot;line-height: 17px; margin: 0px 0px 1.35em;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/37&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; color: #ff0000;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;Aumentato rischio di danno muscolare con alti dosaggi di Simvastatina&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style=&quot;line-height: 17px; margin: 0px 0px 1.35em;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 23px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/36&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; color: #ff0000; text-decoration: underline;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;Parkinson: possibile rischio di tumore della prostata con Stalevo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/24/aggiornamenti-in-cardiologia.html</guid>
                <title>Aggiornamenti in Cardiologia</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/24/aggiornamenti-in-cardiologia.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sat, 24 Mar 2012 23:49:00 +0100</pubDate>
                <description>
                    &lt;div style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; font-size: xx-large;&quot;&gt;ALERT Cardiologia !&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #800080; font-size: x-large;&quot;&gt;American College of Cardiology Meeting&amp;nbsp; &lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/index.php?view=18308&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Studio EXCELLENT: la duplice terapia antiaggregante a 6 mesi non è inferiore a quella a 12 mesi&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;EXCELLENT ( Efficacy of Xience/Promus versus Cypher to rEduce Late Loss in StENT ) è uno studio multicentrico in aperto con un disegno fattoriale 2 × 2. Lo studio ha coinvolto 1.443 pazienti con malattia coronarica, che sono stati assegnati in modo casuale a ricevere uno stent a eluizione di Everolimus o uno stent a rilascio di Sirolimus, e duplice terapia antiaggregante piastrinica [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/?view=18308&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/index.php?view=18306&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Studio PROACT: l’abbassamento dell’INR target può ridurre il sanguinamento dopo sostituzione della valvola aortica&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Lo studio PROACT ( Prospective Randomized On-X Anticoagulation Clinical Trial ) è stato progettato per esaminare la sicurezza e l'efficacia della gestione di pazienti sottoposti a terapia anticoagulante meno aggressiva rispetto a quella attualmente raccomandata dalle lineeguida ACC/AHA dopo impianto della valvola cardiaca meccanica On-X.Nel 2015 saranno disponibili i risultati d [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/?view=18306&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/index.php?view=18305&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Studio RAPS: gli innesti di arteria radiale migliori di quelli di vena safena per CABG a 5 anni&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Lo studio RAPS ( Randomized Multicentre Radial Artery Patency Study ) è stato condotto in 13 Centri in tutto il Canada ed ha riguardato 561 pazienti sottoposti a intervento chirurgico di bypass ( CABG ) per la malattia dei tre vasi. Ciascun paziente è stato randomizzato a ricevere sia un’arteria radiale sia una vena safena, nell’arteria coronarica destra o nell’arteria ci [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/?view=18305&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: x-small;&quot;&gt;News&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cuore.net/index.php?view=18100&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Terapia antitrombotica negli anziani&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;La terapia antitrombotica rappresenta il cardine della terapia per la prevenzione delle recidive di eventi ischemici nei pazienti con episodi di malattia aterotrombotica. Anche se i benefici della terapia farmacologica antitrombotica nei pazienti anziani sono ben stabiliti, questi soggetti sono in genere più vulnerabili agli effetti negativi dei farmaci antitrombotici.Tale maggi [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cuore.net/?view=18100&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cuore.net/index.php?view=18099&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Combinazione di diuretici dell'ansa con diuretici tiazidici nello scompenso cardiaco&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Il sovraccarico di volume è un obiettivo clinico importante nella gestione dello scompenso cardiaco, in genere affrontato utilizzando diuretici dell'ansa. Un importante e impegnativo sottogruppo di pazienti con insufficienza cardiaca presenta un sovraccarico di fluidi malgrado le dosi significative di diuretici dell'ansa.Un approccio possibile per superare la resistenza al diure [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cuore.net/?view=18099&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cuore.net/index.php?view=18087&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Restenosi intra-stent nell’era degli stent a rilascio di farmaco&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;L'introduzione dello stent a eluizione di farmaco si è rivelata un importante passo in avanti nel ridurre i tassi di restenosi e rivascolarizzazione della lesione bersaglio dopo intervento coronarico percutaneo.Tuttavia, la rapida introduzione dello stent a rilascio di farmaco nella pratica clinica standard e l'ampliamento delle indicazioni per intervento coronarico percutaneo i [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cuore.net/?view=18087&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?cat=farmaci&amp;amp;page=2&amp;amp;view=17801&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Efficacia e sicurezza di Vareniclina per la cessazione del fumo in pazienti con malattia cardiovascolare&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;La cessazione del fumo è un elemento chiave della prevenzione secondaria della malattia cardiovascolare.La Vareniclina ( Chantix; in Italia: Champix ), un agonista parziale del recettore nicotinico alfa4beta2, è efficace nella cessazione del fumo in fumatori sani, ma la sua efficacia e sicurezza nei fumatori con malattia cardiovascolare non sono note.Uno studio mult [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?view=17801&amp;amp;page=2&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?cat=farmaci&amp;amp;page=2&amp;amp;view=17776&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Effetto protettivo di supplementi di Acido Folico nel periodo periconcezionale sul rischio di difetti cardiaci congeniti&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Uno studio caso-controllo ha esaminato il potenziale uso protettivo dell’Acido Folico, somministrato nel periodo periconcezionale, sul rischio di difetti cardiaci congeniti, rispetto ad altre malformazioni non-correlate con il Folato.Sono stati analizzati i dati di un registro regionale di grandi dimensioni di difetti alla nascita ( EUROCAT - Northern Netherlands ), riferentesi [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?view=17776&amp;amp;page=2&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo compl&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.net/index.php?view=17908&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Studio EMPHASIS-HF: antagonisti dell'aldosterone confermati nella cura dello scompenso cardiaco&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;I farmaci per il cuore sviluppati prima del 1960 e tuttora in uso sono l’Acido Acetilsalicilico, la Digossina, il Warfarin, e lo Spironolattone. L'antagonismo dello Spironolattone ( e più recentemente dall’Eplerenone ) nei confronti dell'aldosterone è riuscito a ricoprire un ruolo duraturo nella cura dell’insufficienza cardiaca.Quando è stato sviluppato lo Spironolattone [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.net/?view=17908&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/index.php?view=18270&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #008000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: large;&quot;&gt;Farmaci per il diabete di tipo 2: minore sicurezza cardiovascolare con Glimepiride, Glibenclamide, Glipizide e Tolbutamide&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;La Metformina ( MetBay ) sembra essere più sicura di diverse sulfoniluree e meglitinidi per i pazienti con diabete mellito di tipo 2.In uno studio di coorte danese, Glimepiride ( Amaryl, Solosa ), Glibenclamide ( Daonil ), Glipizide ( Glucotrol ) e Tolbutamide ( Orinase ) sono risultati associati ad un aumentato rischio di mortalità per qualsiasi causa e di mortalità cardiovas [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/?view=18270&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/index.php?view=18263&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;2011 Lineeguida ACC/AHA per il trattamento dei pazienti con angina instabile e infarto NSTEMI&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;L'American College of Cardiology ( ACC ) e l'American Heart Association ( AHA ) hanno pubblicato nuove lineeguida riguardo ai pazienti con angina instabile e infarto miocardico senza sopraslivellamento ST ( NSTEMI ).Le attuali lineeguida raccomandano che:• terapia con beta-bloccanti per via orale deve essere somministrata entro le prime 24 ore per i pazienti che non [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologia.net/?view=18263&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.net/index.php?view=17733&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Brilinta: l’FDA ha richiesto analisi supplementari dei dati dello studio PLATO&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;L’FDA ( Food and Drug Administration ) ha rinviato la decisione in merito all'approvazione negli Stati Uniti di Ticagrelor, un nuovo antiaggregante piastrinico di AstraZeneca ( Brilinta ).L’FDA ha richiesto alla società produttrice di Ticagrelor ulteriori analisi dei dati dello studio PLATO.Sono state riscontrate anomalie nei risultati dello studio PLATO, soprattutto d [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.net/?view=17733&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.net/index.php?view=17691&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Effetti indesiderati della statine: studio di popolazione&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;La malattia cardiovascolare è la principale causa di morte prematura e una causa maggiore di disabilità nel Regno Unito. Alcune meta-analisi e politiche nazionali hanno sostenuto l’impiego delle statine nel ridurre il rischio di malattia cardiovascolare nei pazienti ad alto rischio.Oggigiorno le statine sono tra i farmaci più prescritti, ma sono poco note le reazioni avverse corre [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.net/?view=17691&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?page=2&amp;amp;view=17798&quot; target=&quot;_blank&quot;&gt;La copeptina migliora la diagnosi precoce dell’infarto miocardico acuto&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-size: medium;&quot;&gt;L'identificazione precoce dell'infarto del miocardio in pazienti con dolore toracico è cruciale per l'identificazione dei pazienti a rischio e per garantire un inizio veloce del trattamento.E’ stato condotto uno studio per verificare se la determinazione dei livelli di copeptina, un marcatore indiretto per l'arginina-vasopressina, aggiungesse informazione diagnostica alla trop [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?view=17798&amp;amp;page=2&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?page=2&amp;amp;view=17631&quot; target=&quot;_blank&quot;&gt;Dispnea associata a trattamento con Ticagrelor nei pazienti con malattia coronarica stabile&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-size: medium;&quot;&gt;Lo studio ONSET/OFFSET ( A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease ) ha valutato in modo prospettico la funzione cardiaca e polmonare in pazienti con coronaropatia stabile trattati [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?view=17631&amp;amp;page=2&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?page=2&amp;amp;view=17574&quot; target=&quot;_blank&quot;&gt;Associazione tra livelli di Acidi grassi Omega-3 marini e invecchiamento telomerico nei pazienti con malattia coronarica&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-size: medium;&quot;&gt;L’aumentata assunzione alimentare di Acidi grassi Omega-3 marini è associata a un prolungamento della sopravvivenza in pazienti con malattia coronarica, tuttavia il meccanismo alla base di questo effetto protettivo non è stato del tutto compreso.Per studiare l’associazione tra livelli ematici di Acido grasso Omega-3 e i cambiamenti temporali nella lunghezza dei telomeri, un [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.cardiologiaonline.it/index.php?view=17574&amp;amp;page=2&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/21/rischio-di-ictus-nei-pazienti-con-fibrillazione-atriale.html</guid>
                <title>Rischio di ictus nei pazienti con fibrillazione atriale</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/21/rischio-di-ictus-nei-pazienti-con-fibrillazione-atriale.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Wed, 21 Mar 2012 00:30:40 +0100</pubDate>
                <description>
                    &lt;h2 class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagena.it/index.php?view=2235&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: x-large;&quot;&gt;La fibrillazione atriale è correlata a un maggior rischio di demenza nei pazienti con ictus&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;Una meta-analisi ha fornito evidenza a sostegno di un’associazione tra fibrillazione atriale e aumentato rischio di demenza nei pazienti con storia di ictus. Tuttavia, l'associazione non è risultata così ben definita per altre popolazioni. I Ricercatori dell’University of East Anglia a Norfolk, nel Regno Unito, hanno analizzato alcuni database con l’obiettivo di individua [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagena.it/?view=2235&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/21/rischio-di-gotta-nelle-donne.html</guid>
                <title>Rischio di gotta nelle donne</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/21/rischio-di-gotta-nelle-donne.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Wed, 21 Mar 2012 00:25:29 +0100</pubDate>
                <description>
                    &lt;h2 class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.metabolismo.net/index.php?view=18237&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: x-large;&quot;&gt;Bevande ricche di fruttosio associate a rischio di gotta nelle donne&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Le bevande ricche di fruttosio come la soda dolcificata con zucchero e il succo d'arancia possono aumentare i livelli sierici di acido urico e, quindi, il rischio di gotta, ma i dati prospettici sulla correlazione sono limitati.È stato svolto uno studio con l’obiettivo di esaminare la relazione tra assunzione di bevande ricche di fruttosio e il rischio di incidenza di gotta tr [...]&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.metabolismo.net/?view=18237&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/19/farmacia-news-parte-2.html</guid>
                <title>Farmacia News - Parte 2</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/19/farmacia-news-parte-2.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Mon, 19 Mar 2012 01:17:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;listSpace&quot;&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/b7f5d38aaa4e8a553f49c085ee06bb15.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;Riduzione delle biopsie con l’ultrasonografia con elastografia &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/9952cb25b58c5f4832396abf2bcfd66d.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;I pazienti con linfoma di Hodgkin sottoposti a radioterapia presentano un aumentato rischio di ictus e di TIA &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/d50b2d3afe5ec033d560dd1318b2707b.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;Cancro del pancreas e ruolo degli acidi grassi di origine animale &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/d343454654125dd494e0d598510d5913.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;Insufficienza renale con Byetta, un farmaco per il diabete&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/b26f323f0da18551583d2bbf9631ce17.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;Farmaci antinfiammatori selettivi per Cox-2: rischio per la salute pubblica &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/19/farmacia-news-parte-1.html</guid>
                <title>Farmacia News - Parte 1</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/19/farmacia-news-parte-1.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Mon, 19 Mar 2012 01:11:49 +0100</pubDate>
                <description>
                    &lt;div class=&quot;listSpace&quot;&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/f67204d4ca3474c58368df9fb5f0f6bc.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Fratture sottotrocanteriche atipiche del femore con i bifosfonati: l’FDA ha aperto un’indagine &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/a77fee56f3b23fc8cb33e04f4d05132a.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;I tiazolidinedioni possono causare fratture nei pazienti con diabete mellito&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/09236968fe179eba9959ee08bb5bf80f.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Le antracicline nei pazienti con tumore alla mammella avanzato e a rischio cardiaco &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/36e0c72e6254a2992a95c193194f52a5.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Antipsicotici di seconda generazione al loro primo utilizzo: rischio cardiometabolico per i pazienti in età pediatrica &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/f5c981c11d76faa6f95e9dfad16e3eb9.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Vaccinazioni e sviluppo di sindrome di Guillain-Barre &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/17/medicina-news.html</guid>
                <title>Medicina News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/17/medicina-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sat, 17 Mar 2012 14:10:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/d68064201291ce47be8ac5d3918bcb49.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Stato epilettico refrattario: Propofol associato ad arresto cardiaco e morte&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/afe7064469e1509a007b92118aee4524.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Narcolessia: possibile insorgenza di gravi rash cutanei e sintomi psichiatrici con Modafinil&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/b999a556e5f6186b8cba2dd848c22711.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Farmaci antinfiammatori: Etoricoxib non indicato nei pazienti affetti da ipertensione&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/51cf4faf3b8b705fbfa6d97bd1597b7f.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Tysabri può riattivare il virus JC e causare leucoencefalopatia multifocale progressiva&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_news/7e68a92c68139afdaf68b12df5566715.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Le pazienti con carcinoma mammario presentano un rischio residuo di recidiva 5 anni dopo essersi sottoposte a terapia adiuvante&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/17/neurologia-news.html</guid>
                <title>Neurologia News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/17/neurologia-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sat, 17 Mar 2012 12:49:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/2190834cf569ffab46854f84b2124104.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Postmenopausa: il Raloxifene ad alto dosaggio è associato ad un ridotto rischio di alterazione cognitiva &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/b34517c68d949a02746108522f958479.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Stenosi carotidea sintomatica: Aspirina e Clopidogrel nella prevenzione degli emboli &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/ebd774c929a7f6c7e5df19e355f61e23.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Progressione del decadimento cognitivo lieve ad Alzheimer: l’effetto del Donepezil si riduce nel tempo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/8386fa112ba70c3f60b6907d3812bb9e.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Il trattamento precoce con il fattore VII attivato ricombinante riduce la mortalità e la disabilità nell'ictus emorragico&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/b1b14f09e876174212e19b14fa8fed64.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Lyrica nel trattamento dell'epilessia parziale farmaco-resistente&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/15/farmaci-news.html</guid>
                <title>Farmaci News  ( 1 )</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/15/farmaci-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Thu, 15 Mar 2012 00:16:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;ecxpost&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: large/23px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 31px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 29px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 37px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagenasalute.it/index.php?page=3&amp;amp;view=8549&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;La Vitamina-A aumenta la risposta al trattamento per l’infezione da virus HCV&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Le risposte virologiche precoci e sostenute alla terapia standard per l’infezione da virus dell'epatite-C ( HCV ) sono risultate notevolmente migliorate quando i pazienti hanno ricevuto dosi elevate di Vitamina-A.Dopo 48 settimane di trattamento con dosi standard di Interferone peghilato alfa-2b ( PegIntron ), Ribavirina ( Rebetol ), e 30.000 UI/d [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;a style=&quot;line-height: 23px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagenasalute.it/index.php?view=8549&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 23px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: large/23px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 31px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 29px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 37px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagenasalute.it/index.php?page=3&amp;amp;view=8548&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;La Rifaximina nel trattamento della sindrome del colon irritabile senza costipazione&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;L’antibiotico Rifaximina ( Normix, Xifaxan ) ha raggiunto l’endpoint primario in due studi di fase III nella sindrome da intestino irritabile senza costipazione, anche se il miglioramento rispetto al placebo è stato solo modesto.I dati raccolti su un totale di 1.260 pazienti ha indicato che il 40.7% ha presentato un sollievo dei sintomi a segui [...]&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;a style=&quot;line-height: 23px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagenasalute.it/index.php?view=8548&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 23px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: large/23px Arial; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 31px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 29px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 37px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagenasalute.it/index.php?page=3&amp;amp;view=8547&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Il Tapentadolo riduce il dolore nell’osteoartrosi&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Il Tapentadolo ( Palexia, Palexis, Nucynta ), un analgesico ad azione centrale, produce un efficace sollievo del dolore nei pazienti con osteoartrosi del ginocchio, ma con un minor numero di effetti indesiderati gastrointestinali rispetto all’Ossicodone ( OxyContin ).Il Tapentadolo ha significativamente ridotto l'intensità media del dolore dal [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;a style=&quot;line-height: 23px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagenasalute.it/index.php?view=8547&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Leggi articolo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 23px;&quot;&gt;&amp;nbsp;&amp;nbsp;&lt;/div&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 31px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 29px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 37px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagenasalute.it/index.php?page=3&amp;amp;view=8546&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;La Marijuana allevia il dolore neuropatico&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Fumare Marijuana riduce in modo modesto il dolore e altri sintomi associati al dolore neuropatico cronico. La dose più potente utilizzata ha ridotto in media il punteggio del dolore quotidiano di 0.7 punti su una scala di 11 punti ( 5.4 vs 6.1 con placebo ).Inoltre, coloro che hanno fumato erba contenente il 9.4% del principio attivo Tetraidrocannabino [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 23px;&quot;&gt;&lt;a style=&quot;line-height: 23px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.xagenasalute.it/index.php?view=8546&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/14/farmaci-news.html</guid>
                <title>Farmaci News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/14/farmaci-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Wed, 14 Mar 2012 00:35:00 +0100</pubDate>
                <description>
                    &lt;h2 class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaciaonline.net/index.php?view=17697&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Possibili fratture dell’anca, polso e della colonna vertebrale con gli antiacidi appartenenti alla classe degli inibitori della pompa protonica&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Gli inbitori della pompa protonica appaiono associati ad un aumentato rischio di fratture, soprattutto quando utilizzati da donne anziane per un lungo periodo.Gli inibitori della pompa protonica sono una classe di farmaci che comprende: Omeprazolo, Esomeprazolo, Pantoprazolo, Rabeprazolo, Lansoprazolo, oltre a versioni OTC ( over the counter ).Questi farmaci trovano indicaz [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaciaonline.net/?view=17697&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaciaonline.net/index.php?view=17685&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Tumore della prostata avanzato: Provenge, un’immunoterapia cellulare autologa&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;L’Agenzia regolatoria per i farmaci degli Stati Uniti, FDA ( Food and Drug Administration ), ha approvato Provenge ( Sipuleucel-T ), un'immunoterapia cellulare autologa per il carcinoma prostatico metastatizzato, sintomatico o minimamente sintomatico, nei pazienti che non rispondono alla terapia ormonale.L’approvazione è avvenuta sulla base dei risultati di 3 studi clinici c [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaciaonline.net/?view=17685&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaciaonline.net/index.php?page=2&amp;amp;view=17677&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Asma: aggiornamento delle schede tecniche dei medicinali contenenti LABA da parte dell’FDA&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;L’FDA ( Food and Drug Administration ) ha modificato le schede tecniche dei farmaci respiratori che contengono come principio attivo un beta-agonista a lunga durata d’azione ( LABA ).Secondo l’Agenzia per il controllo dei farmaci degli Stati Uniti, nel trattamento dell’asma i LABA dovrebbero essere impiegati solo associati a un farmaco per il controllo della malattia, com [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmaciaonline.net/index.php?view=17677&amp;amp;page=2&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/11/urologia-alert.html</guid>
                <title>Urologia ALERT !</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/11/urologia-alert.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sun, 11 Mar 2012 00:56:00 +0100</pubDate>
                <description>
                    &lt;div&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: xx-large;&quot;&gt;ALERT Urologia !&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;post&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=18474&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #008000;&quot;&gt;FDA: gli inibitori della 5-alfa reduttasi possono aumentare il rischio di una forma più grave di cancro alla prostata &lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;L’FDA ( Food and Drug Administration ) ha informato gli operatori sanitari che la sezione Avvertenze e precauzioni della scheda tecnica per gli inibitori della 5-alfa reduttasi ( 5-ARI ) è stata modificata per inserire le nuove informazioni di sicurezza circa l'aumentato rischio di diagnosi di una forma più grave di cancro alla prostata ( tumore della prostata ad alto grado ). Ques [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/?view=18474&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;APPROFONDIMENTO&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmaci.net/index.php?view=18475&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #0000ff;&quot;&gt;Prevenzione del tumore alla prostata: Finasteride e Dutasteride associati a un aumento dei tumori ad alto grado&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;L’FDA ( Food and Drug Administration ) ha informato gli operatori sanitari che la sezione Avvertenze e precauzioni delle schede tecniche degli inibitori della 5-alfa reduttasi ( 5-ARI ) sono stati rivisti per includere le nuove informazioni di sicurezza circa l'aumentato rischio di diagnosi di una forma più grave di tumore della prostata.La decisione dell’FDA si basa sull’ [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmaci.net/?view=18475&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/09/epatite-news-medfocus-it-4.html</guid>
                <title>Epatite News - MedFocus.it  ( 4 )</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/09/epatite-news-medfocus-it-4.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Fri, 09 Mar 2012 01:04:00 +0100</pubDate>
                <description>
                    &lt;div&gt;&lt;div id=&quot;post-8347&quot; class=&quot;post&quot;&gt;&lt;h3 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.medfocus.it/medicina/epatite/8347-la-combinazione-peginterferone-e-ribavirina-e-piu-efficace-della-combinazione-interferone-e-ribavirina-nel-trattamento-dell-epatite-c-cronica-nei-pazienti-infettati-da-hiv&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;La combinazione Peginterferone e Ribavirina è più efficace della combinazione Interferone e Ribavirina nel trattamento dell’epatite C cronica nei pazienti infettati da HIV&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;L’infezione cronica da virus dell’epatite C ( HCV ) è una delle principali complicanze nelle persone che sono infettate anche dal virus dell’immunodeficienza umana ( HIV... [&lt;span class=&quot;read-more&quot;&gt;&lt;a href=&quot;http://www.medfocus.it/medicina/epatite/8347-la-combinazione-peginterferone-e-ribavirina-e-piu-efficace-della-combinazione-interferone-e-ribavirina-nel-trattamento-dell-epatite-c-cronica-nei-pazienti-infettati-da-hiv&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;] &lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;div id=&quot;post-8408&quot; class=&quot;post&quot;&gt;&lt;h3 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.medfocus.it/medicina/epatite/8408-la-vaccinazione-contro-l-epatite-b-e-associata-ad-un-aumento-del-rischio-di-sclerosi-multipla&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;La vaccinazione contro l’epatite B è associata ad un aumento del rischio di sclerosi multipla&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;Uno studio, coordinato da Ricercatori del Dipartimento di Epidemiologia dell’Harvard School of Public Health a Boston, ha valutato l’esistenza di un link tra il vaccino contro l’epatite B ed un... [&lt;span class=&quot;read-more&quot;&gt;&lt;a href=&quot;http://www.medfocus.it/medicina/epatite/8408-la-vaccinazione-contro-l-epatite-b-e-associata-ad-un-aumento-del-rischio-di-sclerosi-multipla&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;] &lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;div id=&quot;post-8411&quot; class=&quot;post&quot;&gt;&lt;h3 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.medfocus.it/medicina/epatite/8411-prognosi-a-5-anni-dei-pazienti-con-epatite-c-cronica-con-risposta-virologica-sostenuta-dopo-monoterapia-con-interferone&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Prognosi a 5 anni dei pazienti con epatite C cronica con risposta virologica sostenuta dopo monoterapia con Interferone&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;post-excerpt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;L’efficacia del trattamento dell’epatite C cronica è definita come l’assenza di virus rintracciabili a 6 mesi dopo il... [&lt;span class=&quot;read-more&quot;&gt;&lt;a href=&quot;http://www.medfocus.it/medicina/epatite/8411-prognosi-a-5-anni-dei-pazienti-con-epatite-c-cronica-con-risposta-virologica-sostenuta-dopo-monoterapia-con-interferone&quot;&gt;Leggi&lt;/a&gt;&lt;/span&gt;]&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/08/ematologia-news.html</guid>
                <title>Ematologia News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/08/ematologia-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Thu, 08 Mar 2012 01:23:00 +0100</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.ematologia.net/19381-trombosi-arteriosa-nei-giovani-trattati-per-mieloma-multiplo.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Trombosi arteriosa nei giovani trattati per mieloma multiplo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;È stato effettuato uno studio prospettico per valutare il rischio di trombosi arteriosa in 195 pazienti consecutivi di età compresa tra 18 e 65 anni con nuova diagnosi di mieloma multiplo. Tutti i pazienti sono stati trattati con 3 cicli di VAD ( Vincristina, Doxorubicina e Desametasone ) o TAD ( Talidomide, Doxorubicina, Desametasone ) o PAD ( Bortezomib, Doxorubicina [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a href=&quot;http://www.ematologia.net/19381-trombosi-arteriosa-nei-giovani-trattati-per-mieloma-multiplo.html&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.ematologia.net/18589-tossicita-epatica-correlata-al-trattamento-ed-esito-dei-linfomi-non-hodgkin-hcv-positivi.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Tossicità epatica correlata al trattamento ed esito dei linfomi non-Hodgkin HCV-positivi &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Sono stati studiati 160 pazienti positivi al virus dell'epatite C ( HCV ) con linfoma non-Hodgkin ( 59 indolenti, 101 aggressivi ).L'età media dei pazienti era di 67 anni. L’HCV-RNA era presente in 146 soggetti; HBsAg era positivo in sette pazienti. Al momento della diagnosi, il valore di ALT era al di sopra al limite superiore al normale in 67 pazienti.In tu [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a href=&quot;http://www.ematologia.net/18589-tossicita-epatica-correlata-al-trattamento-ed-esito-dei-linfomi-non-hodgkin-hcv-positivi.html&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br /&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.ematologia.net/19261-neoplasie-maligne-secondarie-in-sopravvissuti-a-linfoma-di-hodgkin-pediatrico-trattati-con-chemioterapia-e-con-radioterapia-a-bassa-dose.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Neoplasie maligne secondarie in sopravvissuti a linfoma di Hodgkin pediatrico trattati con chemioterapia e con radioterapia a bassa dose &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Le persone sopravvissute a linfoma di Hodgkin sono a rischio di sviluppare una seconda neoplasia maligna ed è stato teorizzato che questo rischio possa essere attenuato nei pazienti trattati con dosi più basse di radiazioni.È stato condotto il primo studio sugli esiti a lungo termine in una coorte di sopravvissuti a linfoma di Hodgkin pediatrico trattati c [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a href=&quot;http://www.ematologia.net/19261-neoplasie-maligne-secondarie-in-sopravvissuti-a-linfoma-di-hodgkin-pediatrico-trattati-con-chemioterapia-e-con-radioterapia-a-bassa-dose.html&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/07/farmacia-news.html</guid>
                <title>Farmacia News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/07/farmacia-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Wed, 07 Mar 2012 01:20:00 +0100</pubDate>
                <description>
                    &lt;p&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #0000ff; font-size: xx-large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;News Farmacia Xagena&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmaciaonline.net/index.php?view=19893&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Revisione dei farmaci antifibrinolitici: Aprotinina, Acido Aminocaproico e Acido Tranexamico&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;L’EMA ( European Medicines Agency ) ha completato una revisione sui medicinali antifibrinolitici come Aprotinina, Acido Aminocaproico e Acido Tranexamico. Il Comitato per i Prodotti Medicinali per Uso Umano ( CHMP ) ha concluso che i benefici di questi medicinali superano i rischi e ha raccomandato la sospensione del provvedimento di interruzione delle autorizzazioni all'immis [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.farmaciaonline.net/?view=19893&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt; &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.farmaciaonline.net/index.php?view=19833&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Ni&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;mesulide: restrizione delle indicazioni terapeutiche&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Agli operatori sanitari è stata inviata una lettera, concordata con l’Agenzia Italiana del Farmaco ( AIFA ), per fornire importanti informazioni di sicurezza sui medicinali per uso sistemico contenenti Nimesulide.Nel gennaio 2010, a causa di problematiche sulla sicurezza gastrointestinale ed epatica, la Commissione europea aveva richiesto al Comitato per i prodott [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.farmaciaonline.net/?view=19833&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmaciaonline.net/index.php?view=19834&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Farmaci per dimagrire: revisione dei medicinali a base di Orlistat&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;L’Agenzia Europea dei Medicinali ( EMA, European Medicines Agency ) ha completato una revisione dei medicinali che contengono Orlistat, in seguito a problemi circa il possibile rischio di grave danno epatico causato da questi medicinali. Il Comitato Scientifico per i Medicinali ad Uso Umano ( CHMP ) dell'EMA ha concluso che i benefici di Orlistat continuano a superare i rischi [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.farmaciaonline.net/?view=19834&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&amp;nbsp;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/05/osteoporosi-news.html</guid>
                <title>Osteoporosi News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/05/osteoporosi-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Mon, 05 Mar 2012 14:19:00 +0100</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #00ccff; font-size: xx-large;&quot;&gt;&lt;strong&gt;News Osteoporosi Xagena&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.osteoporosi.net/index.php?cat=farmaci&amp;amp;view=16319&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Denosumab nella prevenzione delle fratture in donne in postmenopausa con osteoporosi&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Denosumab ( Prolia ) è un anticorpo monoclonale umano contro RANKL ( receptor activator of nuclear factor-kappaB ligand ), che agisce inibendo lo sviluppo e l’attività degli osteoclasti, diminuendo il riassorbimento osseo e aumentando la densità ossea.Date le sue azioni, Denosumab potrebbe rivelarsi utile nel trattamento dell’osteoporosi.Un gruppo di Ricercatori stat [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.osteoporosi.net/index.php?view=16319&amp;amp;page=1&quot;&gt;Leggi articolo completo&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=18662&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Potenziale aumento del rischio di tumore esofageo con i bifosfonati per os, farmaci per l’osteoporosi&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;L’FDA ( Food and Drug Administration ) ha compiuto una revisione di dati di studi pubblicati per valutare se l'uso di bifosfonati orali fosse associato ad un aumento del rischio di tumore dell'esofago. Gli studi clinici che hanno preso in esame questo rischio sono giunti a risultati contrastanti.I bifosfonati orali sono comunemente utilizzati per la prevenzione e il trattamento [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=18662&amp;amp;page=1&quot;&gt;Leggi articolo completo&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/04/farmaci-notizie.html</guid>
                <title>Farmaci Notizie</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/04/farmaci-notizie.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sun, 04 Mar 2012 20:43:00 +0100</pubDate>
                <description>
                    &lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=24&amp;amp;view=16705&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Prasugrel: eventi avversi non-emorragici&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Non sono state riscontrate differenze tra Prasugrel e Clopidogrel riguardo all’incidenza di gravi eventi avversi, comunemente riportati ( dolore toracico non-cardiaco, ristenosi dell’arteria coronarica, dolore toracico e angina pectoris ) dai pazienti con coronaropatia.La percentuale di eventi avversi occorsi durante il trattamento ( TEAE ) erano simili tra Prasugrel e Clopid [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=16705&amp;amp;page=24&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=25&amp;amp;view=15977&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Vigabatrin negli spasmi infantili: rischio di disturbi del movimento e anormalità MRI&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Vigabatrin ( Sabril ) è un farmaco antiepilettico indicato, in combinazione con altri antiepilettici, nel trattamento dei pazienti con epilessia parziale resistente ( con o senza generalizzazione secondaria ), che non rispondono o che non tollerano, altre combinazioni di farmaci.Vigabatrin è anche indicato in monoterapia nel trattamento degli spasmi infantili ( sindrome di West ). [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15977&amp;amp;page=25&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?page=25&amp;amp;view=15976&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Osteonecrosi della mandibola con i bifosfonati&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;I bifosfonati presentano diverse indicazioni, e sono impiegati in: profilassi e trattamento dell’osteoporosi, trattamento della malattia di Paget, e come parte di alcuni regimi antitumorali, particolarmente per il tumore osseo metastatico e mieloma multiplo.E’ stata effettuata una revisione riguardante il rischio di osteonecrosi della mandibola in associazione all’uso dei b [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/index.php?view=15976&amp;amp;page=25&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/04/farmacovigilanza-reazioni-avverse-da-farmaci.html</guid>
                <title>Farmacovigilanza - Reazioni avverse da farmaci</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/04/farmacovigilanza-reazioni-avverse-da-farmaci.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sun, 04 Mar 2012 19:53:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;post&quot;&gt;&lt;div id=&quot;logo&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/&quot;&gt;&lt;img src=&quot;http://www.farmacovigilanza.net/images/logo.png&quot; alt=&quot;cardiologia&quot; /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: x-large;&quot;&gt;News su reazioni avverse da farmaci segnalate dalle &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: x-large;&quot;&gt;principali Agenzie regolatorie mondiali &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: x-large;&quot;&gt;( FDA, EMA, Health Canada, MHRA, TGA )&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;color: #ff00ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: x-large;&quot;&gt;Farmacovigilanza.net&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: x-large;&quot;&gt;&lt;a href=&quot;http://www.farmacovigilanza.net/&quot;&gt;www.farmacovigilanza.net&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/03/02/protesi-mammarie.html</guid>
                <title>Protesi mammarie</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/03/02/protesi-mammarie.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Fri, 02 Mar 2012 01:38:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://medicinaonline.org/index.php?view=2392&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Protesi mammarie PIP: le donne devono sottoporsi a ecografia mammaria e a visita dal chirurgo plastico&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Non è attualmente dimostrato un legame causa-effetto fra le protesi PIP ( Poly Implant Prothese ) e l’insorgenza di cancro al seno. Su circa 10 milioni di protesi mammarie di diverse marche, impiantate nel mondo sia per motivi estetici che ricostruttivi dopo intervento oncologico, sono stati descritti solo 75 casi di linfoma che origina dalla capsula intorno alla protesi, sia [...] &lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://medicinaonline.org/?view=2392&amp;amp;page=1&quot;&gt;Leggi articolo completo&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://medicinaonline.org/index.php?view=2394&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Ministero della Salute: non c’è evidenza di legame tra le protesi mammarie PIP e tumori&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;Secondo il Ministero della Salute italiano, non esistono prove di un legame tra le protesi PIP ( Poly Implant Prothèse ) e l’insorgenza di tumore, ma esiste solo una maggiore probabilità di rottura delle protesi.Il Ministero della Salute ha emanato un’ordinanza che faccia obbligo a strutture e professionisti che abbiano impiantato protesi PIP di notif [...] &lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://medicinaonline.org/?view=2394&amp;amp;page=1&quot;&gt;Leggi articolo completo&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/02/29/victrelis-nel-trattamento-dell-epatite-c.html</guid>
                <title>Victrelis nel trattamento dell'epatite C</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/02/29/victrelis-nel-trattamento-dell-epatite-c.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Wed, 29 Feb 2012 00:52:00 +0100</pubDate>
                <description>
                    &lt;div style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: xx-large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000;&quot;&gt;FOCUS su: EPATITE&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 23px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 21px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.epatologia.it/index.php?view=18232&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: x-large;&quot;&gt;Epatite C: alta risposta virologica sostenuta associando alla terapia standard Boceprevir, un inibitore della proteasi&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 23px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 21px; font-weight: normal;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #0000ff; font-size: x-large;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;Boceprevir ( Victrelis ) ha migliorato in modo significativo i tassi di risposta virologica sostenuta quando aggiunto alla terapia standard, rispetto alla sola terapia standard a base di PegInterferone ( PegIntron ) e Ribavirina ( Rebetol ).Boceprevir è un inibitore della proteasi che ha come target diretto il genotipo 1 del virus dell’epatite C ( HCV ).Per valutare Boce [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.epatologia.it/?view=18232&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong style=&quot;line-height: 23px; font-weight: bold;&quot;&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/02/27/i-supplementi-a-base-di-vitamina-e-associati-a-tumore-alla-p.html</guid>
                <title>I supplementi a base di Vitamina E associati a tumore alla prostata</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/02/27/i-supplementi-a-base-di-vitamina-e-associati-a-tumore-alla-p.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Mon, 27 Feb 2012 18:53:00 +0100</pubDate>
                <description>
                    &lt;div&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: xx-large;&quot;&gt;&lt;strong&gt;ALERT Benessere &lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;font-family: Arial; color: #008000; font-size: x-large;&quot;&gt;&lt;strong&gt;Journal of American Medical Association ( JAMA )&lt;/strong&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.urologiaonline.net/index.php?view=19151&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #0000ff; font-size: x-large;&quot;&gt;Studio SELECT: la supplementazione di Vitamina-E associata a rischio di cancro alla prostata&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Il rapporto iniziale dello studio SELECT ( Selenium and Vitamin E Cancer Prevention Trial ) non ha messo in luce una riduzione del rischio di carcinoma prostatico con supplementi di Selenio o Vitamina E, ma un aumento non-significativo del rischio di questo tumore con la Vitamina-E.Un follow-up più lungo e un numero maggiore di eventi di cancro alla prostata hanno forni [...] &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.urologiaonline.net/?view=19151&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/02/27/tumore-alla-mammella-report-sabcs.html</guid>
                <title>Tumore alla mammella - Report SABCS</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/02/27/tumore-alla-mammella-report-sabcs.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Mon, 27 Feb 2012 00:34:00 +0100</pubDate>
                <description>
                    &lt;div&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: xx-large;&quot;&gt;&lt;strong&gt;REPORT Tumore mammario &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #339966;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: x-small;&quot;&gt;&lt;span style=&quot;font-size: xx-large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #00ffff;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman;&quot;&gt;San Antonio Breast Cancer Symposium&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.ginecologia.net/index.php?cat=farmaci&amp;amp;view=17748&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Tumore alla mammella: l’Acido Zoledronico non migliora la sopravvivenza libera da malattia&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;L'Acido Zoledronico ( Zometa ) non ha migliorato la sopravvivenza libera da malattia tra le donne con carcinoma mammario in fase 2/3 in base ai risultati dello studio AZURE ( Adjuvant Treatment with Zoledronic Acid in Stage 2/3 Breast Cancer ).Tra le 1.101 pazienti che erano da 5 anni in menopausa, è stato riscontrato un miglioramento della sopravvivenza generale del 29%.L [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;a href=&quot;http://www.ginecologia.net/?view=17748&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt; &lt;/span&gt;&lt;/strong&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.ginecologia.net/index.php?view=17744&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Tossicità della terapia endocrina adiuvante nelle pazienti in postmenopausa affette da tumore alla mammella&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;L’obiettivo dello studio condotto da Ricercatori del Princess Margaret Hospital di Toronto in Canada, è stato quello di determinare la differenza riguardo ai gravi eventi avversi tra gli inibitori dell'aromatasi e il Tamoxifene ( Nolvadex), e di verificare l’eventuale miglioramento di questi eventi avversi con il passaggio agli inibitori dell’aromatasi dopo 2-3 anni di Tamoxifene. [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;a href=&quot;http://www.ginecologia.net/?view=17744&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.ginecologia.net/index.php?cat=farmaci&amp;amp;view=17745&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000;&quot;&gt;Prevenzione della recidiva di tumore alla mammela: Exemestane simile ad Anastrozolo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Uno studio che ha messo a confronto due inibitori dell'aromatasi come terapia adiuvante nelle donne in postmenopausa con carcinoma mammario positivo per il recettore ormonale non ha rilevato differenze tra Exemestane ( Aromasin ) e Anastrozolo ( Arimidex ).Questi i risultati dello studio MA27.L'ipotesi di partenza dello studio era che Exemestane, per il fatto di esser [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;a href=&quot;http://www.ginecologia.net/?view=17745&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/02/25/ricerca-informazioni-su-reumatologia.html</guid>
                <title>Ricerca informazioni su: Reumatologia</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/02/25/ricerca-informazioni-su-reumatologia.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Sat, 25 Feb 2012 02:45:00 +0100</pubDate>
                <description>
                    &lt;div&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: xx-large;&quot;&gt;&lt;strong&gt;Risorse in Reumatologia&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;1) News &amp;amp; Farmaci su Reumatologia -&amp;gt; Reumatologia.net&amp;nbsp; &lt;/strong&gt;&lt;/span&gt;&lt;a href=&quot;http://www.reumatologia.net/&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;www.reumatologia.net&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;2) Approfondimenti in Reumatologia&amp;nbsp; -&amp;gt; ReumatologiaOnline.net&amp;nbsp; &lt;/strong&gt;&lt;/span&gt;&lt;a href=&quot;http://www.reumatologiaonline.net/&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;www.reumatologiaonline.net&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;3) News &amp;amp; Farmaci su Artrite -&amp;gt; ArtriteOnline.net&amp;nbsp; &lt;/strong&gt;&lt;/span&gt;&lt;a href=&quot;http://www.artriteonline.net/&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;www.artriteonline.net&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;4) News &amp;amp; Farmaci su Fibromialgia -&amp;gt; FibromialgiaOnline.net&amp;nbsp;&amp;nbsp; &lt;/strong&gt;&lt;/span&gt;&lt;a href=&quot;http://www.fibromialgiaonline.net/&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;www.fibromialgiaonline.net&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;div&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;5) News &amp;amp; Farmaci su Lupus eritematoso sistemico -&amp;gt; LupusOnline.net&amp;nbsp; &lt;/strong&gt;&lt;/span&gt;&lt;a href=&quot;http://www.lupusonline.net/&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;www.lupusonline.net&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagenafarmacia.myblog.it/archive/2012/02/24/tumori-news.html</guid>
                <title>Tumori News</title>
                <link>http://xagenafarmacia.myblog.it/archive/2012/02/24/tumori-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Farmacia</category>
                                                <pubDate>Fri, 24 Feb 2012 01:23:10 +0100</pubDate>
                <description>
                    &lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;span style=&quot;color: #ff0000; font-size: xx-large;&quot;&gt;&lt;strong&gt;NEWS ONCOLOGIA XAGENA&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncologiamedica.net/index.php?cat=farmaci&amp;amp;view=18130&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #008000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Attività antitumorale significativa e sostenuta dopo Docetaxel nel tumore alla prostata resistente a castrazione con l’inibitore di CYP17 Abiraterone&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;È stato condotto uno studio per valutare l’attività antitumorale di Abiraterone acetato, un inibitore orale specifico e irreversibile di CYP17 in pazienti trattati con Docetaxel ( Taxotere ) con tumore alla prostata resistente a castrazione.Nello studio multicentrico di fase II, Abiraterone 1000 mg è stato somministrato 1 volta al giorno in modo continuato.L’en [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncologiamedica.net/?view=18130&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncologiamedica.net/index.php?cat=farmaci&amp;amp;view=18128&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Enzastaurina rispetto a Lomustina nel trattamento del glioblastoma intracranico ricorrente&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Uno studio di fase III in aperto ha confrontato l’efficacia e lasicurezza di Enzastaurina versus Lomustina ( CeeNU ) in pazienti con glioblastoma ricorrente ( di grado 4 secondo l’Organizzazione mondiale della sanità [ OMS ] ).I pazienti sono stati assegnati in maniera casuale, e in rapporto 2:1 a ricevere cicli di 6 settimane di Enzastaurina 500 mg/die ( dose di carico 1,12 [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncologiamedica.net/?view=18128&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncologiamedica.net/index.php?cat=farmaci&amp;amp;view=18126&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Pertuzumab e Trastuzumab in pazienti con carcinoma mammario metastatico positivo per EGFR2 progredito durante la precedente terapia con Trastuzumab&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Pertuzumab ( Omnitarg ), un anticorpo monoclonale che ha come bersaglio HER2 ( epidermal growth factor receptor 2 ) umano, inibisce in modo potente la dimerizzazione di HER2 e i pathway di segnalazione mediati da HER.Pertuzumab e l'anticorpo monoclonale contro HER2. Trastuzumab ( Herceptin ), hanno meccanismi di azione complementari e portano a un aumento dell'attività antitumor [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncologiamedica.net/?view=18126&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncologiamedica.net/index.php?cat=farmaci&amp;amp;view=18120&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Temozolomide versus Procarbazina, Lomustina e Vincristina nel glioma ad alto grado ricorrente&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Temozolomide ( Temodal ) è un agente alchilante approvato per il trattamento del glioma di alto grado, ma non esistono confronti prospettici con chemioterapia a base di Nitrosourea.Sono stati riportati i risultati del primo studio randomizzato su Procarbazina ( Natulan ), Lomustina ( CeeNU ) e Vincristina versus Temozolomide in pazienti naive per la chemioterapia con glioma di a [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncologiamedica.net/?view=18120&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                </channel>
</rss>
